Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

10.10
+0.00500.05%
Post-market: 10.100.00000.00%16:14 EDT
Volume:1.14M
Turnover:11.50M
Market Cap:445.91M
PE:-3.27
High:10.13
Open:10.11
Low:10.09
Close:10.09
Loading ...

Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview

Reuters
·
Yesterday

Leerink Partners Keeps Their Hold Rating on iTeos Therapeutics (ITOS)

TIPRANKS
·
22 Jul

Wedbush Adjusts Price Target on iTeos Therapeutics to $10.50 From $12, Maintains Neutral Rating

MT Newswires Live
·
22 Jul

iTeos Therapeutics downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
21 Jul

iTeos Therapeutics Agrees to be Acquired by Concentra Biosciences

MT Newswires Live
·
21 Jul

BRIEF-Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right

Reuters
·
21 Jul

GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab

TIPRANKS
·
16 Jul

iTeos Therapeutics Holds Annual Stockholders Meeting

TIPRANKS
·
18 Jun

Iteos Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
18 Jun

CEO Michel Detheux Reports Disposal of Common Shares of iTeos Therapeutics Inc

Reuters
·
12 Jun

Iteos Therapeutics CEO Michel Detheux Reports Disposal of Common Shares

Reuters
·
07 Jun

Tim Van Hauwermeiren Resigns from iTeos Therapeutics Board of Directors

Reuters
·
06 Jun

iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects

TIPRANKS
·
30 May

iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down

TIPRANKS
·
28 May

BRIEF-I Teos Therapeutics Inc Expected Severance Costs Of $21.8 Million To $24.7 Million

Reuters
·
28 May

iTeos Therapeutics Cut to Neutral From Outperform by Wedbush

Dow Jones
·
28 May

Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10

MT Newswires Live
·
28 May

iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision

TIPRANKS
·
28 May

BUZZ-ITeos rises on plans to explore asset sales, use cash reserves

Reuters
·
28 May

iTeos plans to shut down operations after cancer therapy setback

Reuters
·
28 May